A pilot first in human study of Thymosin-beta-4 in the treatment of patients after an acute ST segment elevation myocardial infarction (STEMI) or heart attack
Latest Information Update: 22 Jun 2016
Price :
$35 *
At a glance
- Drugs Timbetasin (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; First in man; Therapeutic Use
- 22 Jun 2016 New trial record
- 14 Jun 2016 According to a RegeneRx Biopharmaceuticals media release, results from this study were published in International Society for Cellular Therapy.
- 14 Jun 2016 Results published in the Media Release